These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 3536151)
1. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Gordon DJ; Knoke J; Probstfield JL; Superko R; Tyroler HA Circulation; 1986 Dec; 74(6):1217-25. PubMed ID: 3536151 [TBL] [Abstract][Full Text] [Related]
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA; 1984 Jan; 251(3):351-64. PubMed ID: 6361299 [TBL] [Abstract][Full Text] [Related]
3. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Rifkind BM Am J Cardiol; 1984 Aug; 54(5):30C-34C. PubMed ID: 6382999 [TBL] [Abstract][Full Text] [Related]
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA; 1984 Jan; 251(3):365-74. PubMed ID: 6361300 [TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. Schaefer EJ; Lamon-Fava S; Jenner JL; McNamara JR; Ordovas JM; Davis CE; Abolafia JM; Lippel K; Levy RI JAMA; 1994 Apr; 271(13):999-1003. PubMed ID: 8139085 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157 [TBL] [Abstract][Full Text] [Related]
8. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041 [TBL] [Abstract][Full Text] [Related]
9. Report on the Lipid Research Clinic trials. Levy RI Eur Heart J; 1987 Aug; 8 Suppl E():45-53. PubMed ID: 3315677 [TBL] [Abstract][Full Text] [Related]
10. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med; 1992 Jul; 152(7):1399-410. PubMed ID: 1627020 [TBL] [Abstract][Full Text] [Related]
11. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database. Peters TK Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803 [TBL] [Abstract][Full Text] [Related]
12. Dietary and other correlates of changes in total and low density lipoprotein cholesterol in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Glueck CJ; Gordon DJ; Nelson JJ; Davis CE; Tyroler HA Am J Clin Nutr; 1986 Oct; 44(4):489-500. PubMed ID: 3532756 [TBL] [Abstract][Full Text] [Related]
13. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Levy RI; Brensike JF; Epstein SE; Kelsey SF; Passamani ER; Richardson JM; Loh IK; Stone NJ; Aldrich RF; Battaglini JW Circulation; 1984 Feb; 69(2):325-37. PubMed ID: 6360415 [TBL] [Abstract][Full Text] [Related]
14. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235 [TBL] [Abstract][Full Text] [Related]
16. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227 [TBL] [Abstract][Full Text] [Related]
17. Seasonal cholesterol cycles: the Lipid Research Clinics Coronary Primary Prevention Trial placebo group. Gordon DJ; Trost DC; Hyde J; Whaley FS; Hannan PJ; Jacobs DR; Ekelund LG Circulation; 1987 Dec; 76(6):1224-31. PubMed ID: 3315294 [TBL] [Abstract][Full Text] [Related]
18. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN. J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Wang TD; Chen WJ; Chien KL; Seh-Yi Su SS; Hsu HC; Chen MF; Liau CS; Lee YT Am J Cardiol; 2001 Oct; 88(7):737-43. PubMed ID: 11589839 [TBL] [Abstract][Full Text] [Related]